FDA Opts For Full, Rather Than Accelerated, Approval Of GSK’s Votrient In Sarcoma

Despite advisory committee discussion about a possible accelerated approval for pazopanib with a confirmatory study to assess symptom benefit, the agency opted to grant regular approval, as had been requested by GlaxoSmithKline.